{ 'indexed': {'date-parts': [[2024, 8, 11]], 'date-time': '2024-08-11T00:28:19Z', 'timestamp': 1723336099552},
'publisher-location': 'Berlin, Heidelberg',
'reference-count': 117,
'publisher': 'Springer Berlin Heidelberg',
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2024]]},
'DOI': '10.1007/82_2024_268',
'type': 'book-chapter',
'created': {'date-parts': [[2024, 8, 10]], 'date-time': '2024-08-10T13:04:12Z', 'timestamp': 1723295052000},
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities',
'prefix': '10.1007',
'author': [{'given': 'Daniele', 'family': 'Focosi', 'sequence': 'first', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2024, 8, 11]]},
'reference': [ { 'key': '268_CR1',
'doi-asserted-by': 'publisher',
'unstructured': 'ACTIV-3/TICO LY-CoV555 Study Group (2020) A neutralizing monoclonal '
'antibody for hospitalized patients with Covid-19. N Engl J Med '
'384(10):905–914. https://doi.org/10.1056/NEJMoa2033130',
'DOI': '10.1056/NEJMoa2033130'},
{ 'key': '268_CR2',
'unstructured': 'ACTIV-3: Therapeutics for Inpatients With COVID-19—Full Text '
'View—ClinicalTrials.gov'},
{ 'key': '268_CR3',
'doi-asserted-by': 'publisher',
'unstructured': 'Anderson TS, O’Donoghue A, Mechanic O, Dechen T, Stevens J (2022) '
'Administration of anti–SARS-CoV-2 monoclonal antibodies after US food '
'and drug administration deauthorization. JAMA Netw Open 5(8):e2228997-e. '
'https://doi.org/10.1001/jamanetworkopen.2022.28997',
'DOI': '10.1001/jamanetworkopen.2022.28997'},
{ 'key': '268_CR4',
'unstructured': 'AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE '
'Phase III outpatient treatment trial (2022). Accessed online at '
'https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html '
'on 22 Feb 2022'},
{ 'issue': 'S0085–2538',
'key': '268_CR5',
'doi-asserted-by': 'publisher',
'first-page': '00383',
'DOI': '10.1016/j.kint.2022.05.008',
'volume': '22',
'author': 'I Benotmane',
'year': '2022',
'unstructured': 'Benotmane I, Velay A, Thaunat O, Vargas GG, Olagne J, Fafi-Kremer S et '
'al (2022) Pre-exposure prophylaxis with Evusheld™ elicits limited '
'neutralizing activity against the Omicron variant in kidney transplant '
'patients. Kidney Int 22(S0085–2538):00383. '
'https://doi.org/10.1016/j.kint.2022.05.008',
'journal-title': 'Kidney Int'},
{ 'issue': '7838',
'key': '268_CR6',
'doi-asserted-by': 'publisher',
'first-page': '485',
'DOI': '10.1038/s41586-020-2838-z',
'volume': '588',
'author': 'S Bournazos',
'year': '2020',
'unstructured': 'Bournazos S, Corti D, Virgin HW, Ravetch JV (2020) Fc-optimized '
'antibodies elicit CD8 immunity to viral respiratory infection. Nature '
'588(7838):485–490. https://doi.org/10.1038/s41586-020-2838-z',
'journal-title': 'Nature'},
{ 'key': '268_CR7',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-021-04386-2',
'author': 'E Cameroni',
'year': '2021',
'unstructured': 'Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K et al '
'(2021) Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron '
'antigenic shift. Nature. https://doi.org/10.1038/s41586-021-04386-2',
'journal-title': 'Nature'},
{ 'key': '268_CR8',
'doi-asserted-by': 'publisher',
'unstructured': 'Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A et al (2022) Imprinted '
'SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. '
'Nature. https://doi.org/10.1038/s41586-022-05644-7',
'DOI': '10.1038/s41586-022-05644-7'},
{ 'key': '268_CR9',
'doi-asserted-by': 'crossref',
'unstructured': 'Casadevall A, Focosi D (2023) SARS-CoV-2 variants resistant to '
'monoclonal antibodies in immunocompromised patients is a public health '
'concern. J Clin Invest',
'DOI': '10.1172/JCI168603'},
{ 'key': '268_CR10',
'doi-asserted-by': 'publisher',
'unstructured': 'Dalakas MC, Spaeth PJ (2021) The importance of FcRn in '
'neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, '
'IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol '
'Disord. https://doi.org/10.1177/1756286421997381',
'DOI': '10.1177/1756286421997381'},
{ 'issue': '9',
'key': '268_CR11',
'doi-asserted-by': 'publisher',
'first-page': '886',
'DOI': '10.1097/inf.0000000000001916',
'volume': '37',
'author': 'JB Domachowske',
'year': '2018',
'unstructured': 'Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T et al '
'(2018) Safety, tolerability and pharmacokinetics of MEDI8897, an '
'extended half-life single-dose respiratory syncytial virus prefusion '
'F-targeting monoclonal antibody administered as a single dose to healthy '
'preterm infants. Pediatr Infect Dis J 37(9):886–892. '
'https://doi.org/10.1097/inf.0000000000001916',
'journal-title': 'Pediatr Infect Dis J'},
{ 'key': '268_CR12',
'doi-asserted-by': 'crossref',
'unstructured': 'Drysdale M, Gibbons DC, Singh M, Rolland C, Lavoie L, Skingsley A et al '
'(2024) Real-world effectiveness of sotrovimab for the treatment of '
'SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a '
'systematic literature review. Infection 52:1–17',
'DOI': '10.1007/s15010-023-02098-5'},
{ 'key': '268_CR13',
'unstructured': 'ETF statement on the loss of activity of anti-spike protein monoclonal '
'antibodies due to emerging SARS-CoV-2 variants of concern (2022). 9 '
'December 2022 EMA/931457/2022. Accessed online at '
'https://www.ema.europa.eu/en/documents/public-statement/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2_en.pdf'},
{ 'key': '268_CR14',
'unstructured': 'ETF warns that monoclonal antibodies may not be effective against '
'emerging strains of SARS-CoV-2 (2023). Accessed online at '
'https://www.ema.europa.eu/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2 '
'on 24 Jan 2023'},
{ 'issue': '5',
'key': '268_CR15',
'doi-asserted-by': 'publisher',
'first-page': '658',
'DOI': '10.7326/m22-3428',
'volume': '176',
'author': 'TH Evering',
'year': '2023',
'unstructured': 'Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA et al '
'(2023) Safety and efficacy of combination SARS-CoV-2 neutralizing '
'monoclonal antibodies Amubarvimab plus Romlusevimab in nonhospitalized '
'patients With COVID-19. Ann Intern Med 176(5):658–666. '
'https://doi.org/10.7326/m22-3428',
'journal-title': 'Ann Intern Med'},
{ 'key': '268_CR16',
'unstructured': 'Fact sheet for healthcare providers: emergency use authorization for '
'bebtelovimab (2022). Accessed online at '
'https://www.fda.gov/media/156152/download on 21 Feb 2022'},
{ 'key': '268_CR17',
'unstructured': 'FDA (2022) Coronavirus (COVID-19) update: FDA authorizes New monoclonal '
'antibody for treatment of COVID-19 that retains activity against Omicron '
'variant. Accessed online at '
'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains '
'on 17 Feb 2022'},
{ 'key': '268_CR18',
'unstructured': 'FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region '
'(2022). Accessed online at '
'https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region '
'on 1 Dec 2022'},
{ 'key': '268_CR19',
'unstructured': 'FDA announces Evusheld is not currently authorized for emergency use in '
'the U.S. (2023) Accessed online at '
'https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us '
'on 3 Feb 2023'},
{ 'key': '268_CR20',
'unstructured': 'FDA Statement (2022) Coronavirus (COVID-19) update: FDA limits use of '
'certain monoclonal antibodies to treat COVID-19 due to the Omicron '
'variant. '
'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron '
'Accessed 8 June 2023'},
{ 'key': '268_CR21',
'unstructured': 'FDA updates Sotrovimab emergency use authorization. March 30, 2022. '
'https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization '
'Accessed 9 June 2023'},
{ 'key': '268_CR22',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/rmv.2231',
'author': 'D Focosi',
'year': '2021',
'unstructured': 'Focosi D, Maggi F (2021) Neutralising antibody escape of SARS-CoV-2 '
'spike protein: risk assessment for antibody-based Covid-19 therapeutics '
'and vaccines. Rev Med Virol. https://doi.org/10.1002/rmv.2231',
'journal-title': 'Rev Med Virol'},
{ 'key': '268_CR23',
'doi-asserted-by': 'publisher',
'first-page': '219',
'DOI': '10.2217/fmb-2021-0286',
'volume': '17',
'author': 'D Focosi',
'year': '2022',
'unstructured': 'Focosi D, Maggi F, McConnell S, Casadevall A (2022a) Spike mutations in '
'SARS-CoV-2 AY sublineages of delta variant of concern: implications for '
'the future of the pandemic. Future Microbiol 17:219–221. '
'https://doi.org/10.2217/fmb-2021-0286',
'journal-title': 'Future Microbiol'},
{ 'issue': '1',
'key': '268_CR24',
'doi-asserted-by': 'crossref',
'first-page': '29',
'DOI': '10.3390/ijms23010029',
'volume': '23',
'author': 'D Focosi',
'year': '2022',
'unstructured': 'Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A (2022b) '
'Analysis of immune escape variants from antibody-based therapeutics '
'against COVID-19: a systematic review. Int J Mol Sci 23(1):29',
'journal-title': 'Int J Mol Sci'},
{ 'issue': '11',
'key': '268_CR25',
'doi-asserted-by': 'publisher',
'first-page': '00311',
'DOI': '10.1016/S1473-3099(22)00311-5',
'volume': '22',
'author': 'D Focosi',
'year': '2022',
'unstructured': 'Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M '
'(2022c) Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect '
'Dis 22(11):00311–00315. https://doi.org/10.1016/S1473-3099(22)00311-5',
'journal-title': 'Lancet Infect Dis'},
{ 'issue': '3',
'key': '268_CR26',
'doi-asserted-by': 'crossref',
'first-page': '2264',
'DOI': '10.3390/ijms24032264',
'volume': '24',
'author': 'D Focosi',
'year': '2023',
'unstructured': 'Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A (2023a) '
'Convergent evolution in SARS-CoV-2 Spike creates a variant soup from '
'which new COVID-19 waves emerge. Int J Mol Sci 24(3):2264',
'journal-title': 'Int J Mol Sci'},
{ 'key': '268_CR27',
'doi-asserted-by': 'crossref',
'unstructured': 'Focosi D (2023) A web tool to estimate baaseline anti-Spike monoclonal '
'antibody efficacy based on regional genomic surveillance. Viruses '
'15(5):1048',
'DOI': '10.3390/v15051048'},
{ 'key': '268_CR28',
'doi-asserted-by': 'crossref',
'unstructured': 'Focosi D, Maggi F (2023) Respiratory delivery of passive immunotherapies '
'for SARS-CoV-2 prophylaxis and therapy. Hum Vaccines Immunotherap 19(2)',
'DOI': '10.1080/21645515.2023.2260040'},
{ 'key': '268_CR29',
'doi-asserted-by': 'publisher',
'unstructured': 'Focosi D, Tuccori M (2022) Prescription of anti-spike monoclonal '
'antibodies in COVID-19 patients with resistant SARS-CoV-2 variants in '
'Italy. Pathogens (Basel, Switzerland) 11(8). '
'https://doi.org/10.3390/pathogens11080823',
'DOI': '10.3390/pathogens11080823'},
{ 'key': '268_CR30',
'doi-asserted-by': 'publisher',
'unstructured': 'Focosi D, McConnell S, Sullivan DJ, Casadevall A (2023b) Analysis of '
'SARS-CoV-2 mutations associated with resistance to therapeutic '
'monoclonal antibodies that emerge after treatment. Drug Resist Updates '
'100991. https://doi.org/10.1016/j.drup.2023.100991',
'DOI': '10.1016/j.drup.2023.100991'},
{ 'key': '268_CR31',
'unstructured': 'Francica J, Rosenthal K, Ren K, Flores DJ et al (2023) The SARS-CoV-2 '
'monoclonal antibody AZD3152 potently neutralises historical and '
'currently circulating variants. ECCMID. Copenhagen'},
{ 'key': '268_CR32',
'doi-asserted-by': 'publisher',
'unstructured': 'Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J et al (2021) '
'Effect of bamlanivimab as monotherapy or in combination with etesevimab '
'on viral load in patients with mild to moderate COVID-19: a randomized '
'clinical trial. JAMA 325(7):632–644. '
'https://doi.org/10.1001/jama.2021.0202%JJAMA',
'DOI': '10.1001/jama.2021.0202%JJAMA'},
{ 'key': '268_CR42',
'doi-asserted-by': 'crossref',
'unstructured': 'Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G et al '
'(2022) Casirivimab and imdevimab in patients admitted to hospital with '
'COVID-19 (RECOVERY): a randomised, controlled, open-label, platform '
'trial. Lancet 399(10325):665–676. '
'https://doi.org/10.1016/S0140-6736(22)00163-5',
'DOI': '10.1016/S0140-6736(22)00163-5'},
{ 'key': '268_CR33',
'doi-asserted-by': 'publisher',
'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR et '
'al (2021) Early treatment for Covid-19 with SARS-CoV-2 neutralizing '
'antibody sotrovimab. N Engl J Med 385:1941–1950. '
'https://doi.org/10.1056/NEJMoa2107934',
'DOI': '10.1056/NEJMoa2107934'},
{ 'issue': '10',
'key': '268_CR34',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.ppat.1009542',
'volume': '17',
'author': 'K Haga',
'year': '2021',
'unstructured': 'Haga K, Takai-Todaka R, Matsumura Y, Song C, Takano T, Tojo T et al '
'(2021) Nasal delivery of single-domain antibody improves symptoms of '
'SARS-CoV-2 infection in an animal model. PLoS Pathog 17(10):e1009542. '
'https://doi.org/10.1371/journal.ppat.1009542',
'journal-title': 'PLoS Pathog'},
{ 'key': '268_CR35',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/ve/veac104',
'author': 'PJ Halfmann',
'year': '2022',
'unstructured': 'Halfmann PJ, Minor NR, Haddock LA III, Maddox R, Moreno GK, Braun KM et '
'al (2022) Evolution of a globally unique SARS-CoV-2 Spike E484T '
'monoclonal antibody escape mutation in a persistently infected, '
'immunocompromised individual. Virus Evol. '
'https://doi.org/10.1093/ve/veac104',
'journal-title': 'Virus Evol'},
{ 'issue': '6428',
'key': '268_CR36',
'doi-asserted-by': 'publisher',
'first-page': '446',
'DOI': '10.1038/363446a0',
'volume': '363',
'author': 'C Hamers-Casterman',
'year': '1993',
'unstructured': 'Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, '
'Songa EB et al (1993) Naturally occurring antibodies devoid of light '
'chains. Nature 363(6428):446–448. https://doi.org/10.1038/363446a0',
'journal-title': 'Nature'},
{ 'key': '268_CR37',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.virs.2023.07.003',
'author': 'Q Han',
'year': '2023',
'unstructured': 'Han Q, Wang S, Wang Z, Zhang C, Wang X, Feng N et al (2023) Nanobodies '
'with cross-neutralizing activity provide prominent therapeutic efficacy '
'in mild and severe COVID-19 rodent models. Virologica Sinica. '
'https://doi.org/10.1016/j.virs.2023.07.003',
'journal-title': 'Virologica Sinica'},
{ 'issue': '2',
'key': '268_CR38',
'doi-asserted-by': 'crossref',
'first-page': '530',
'DOI': '10.3390/v15020530',
'volume': '15',
'author': 'L Hao',
'year': '2023',
'unstructured': 'Hao L, Hsiang T-Y, Dalmat RR, Ireton R, Morton JF, Stokes C et al (2023) '
'Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal '
'protection against Omicron. Viruses 15(2):530',
'journal-title': 'Viruses'},
{ 'key': '268_CR39',
'doi-asserted-by': 'crossref',
'unstructured': 'Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J et al '
'(2022) Comparison of the risk of hospitalisation among BA.1 and BA.2 '
'COVID-19 cases treated with Sotrovimab in the community in England. '
'Influenza Other Respi Viruses 17(5):e13150. '
'https://doi.org/10.1111/irv.13150',
'DOI': '10.1111/irv.13150'},
{ 'issue': '2',
'key': '268_CR40',
'doi-asserted-by': 'publisher',
'first-page': '250',
'DOI': '10.1067/mai.2001.116576',
'volume': '108',
'author': 'TK Hart',
'year': '2001',
'unstructured': 'Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE '
'et al (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), '
'a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J '
'Allergy Clin Immunol 108(2):250–257. '
'https://doi.org/10.1067/mai.2001.116576',
'journal-title': 'J Allergy Clin Immunol'},
{ 'key': '268_CR41',
'doi-asserted-by': 'publisher',
'unstructured': 'He Q, Wu L, Xu Z, Wang X, Xie Y, Chai Y et al (2023) An updated atlas of '
'antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and '
'XBB. Cell Rep Med 4(4):100991. '
'https://doi.org/10.1016/j.xcrm.2023.100991',
'DOI': '10.1016/j.xcrm.2023.100991'},
{ 'key': '268_CR43',
'doi-asserted-by': 'crossref',
'unstructured': 'Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan Y-H et al '
'(2021) Structural definition of a pan-sarbecovirus neutralizing epitope '
'on the spike S2 subunit. Commun Biol. '
'https://doi.org/10.1038/s42003-022-03262-7',
'DOI': '10.1101/2021.08.02.454829'},
{ 'key': '268_CR44',
'unstructured': 'IDSA Guidelines on the Treatment and Management of Patients with '
'COVID-19 (2022). Accessed online at '
'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ '
'on 9 Feb 2022'},
{ 'issue': '7906',
'key': '268_CR45',
'doi-asserted-by': 'publisher',
'first-page': '553',
'DOI': '10.1038/s41586-022-04594-4',
'volume': '604',
'author': 'S Iketani',
'year': '2022',
'unstructured': 'Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M et al (2022) Antibody '
'evasion properties of SARS-CoV-2 Omicron sublineages. Nature '
'604(7906):553–556. https://doi.org/10.1038/s41586-022-04594-4',
'journal-title': 'Nature'},
{ 'key': '268_CR46',
'doi-asserted-by': 'publisher',
'unstructured': 'Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S et al (2022) '
'Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. '
'N Engl J Med. https://doi.org/10.1056/NEJMc2214302',
'DOI': '10.1056/NEJMc2214302'},
{ 'key': '268_CR47',
'doi-asserted-by': 'crossref',
'unstructured': 'Isa F, Forleo-Neto E, Meyer J, Zheng W, Rasmussen S, Armas D et al '
'(2021) Repeat subcutaneous administration of REGEN-COV® in adults is '
'well-tolerated and prevents the occurrence of COVID-19. Int J Infect '
'Dis. https://doi.org/10.1016/j.ijid.2022.06.045',
'DOI': '10.1016/j.ijid.2022.06.045'},
{ 'key': '268_CR48',
'doi-asserted-by': 'publisher',
'unstructured': 'Ison MG, Weinstein DF, Dobryanska M, Holmes A, Phelan A-M, Li Y et al '
'(2023) Prevention of COVID-19 following a single intramuscular '
'administration of Adintrevimab: results from a phase 2/3 randomized, '
'double-blind, placebo-controlled trial (EVADE). Open Forum Infect Dis '
'10(7). https://doi.org/10.1093/ofid/ofad314',
'DOI': '10.1093/ofid/ofad314'},
{ 'key': '268_CR49',
'doi-asserted-by': 'publisher',
'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, '
'Delos Reyes V et al (2022) Molnupiravir for oral treatment of Covid-19 '
'in nonhospitalized patients. N Engl J Med 386(6):509–520. '
'https://doi.org/10.1056/NEJMoa2116044',
'DOI': '10.1056/NEJMoa2116044'},
{ 'key': '268_CR50',
'doi-asserted-by': 'crossref',
'unstructured': 'Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Alfredo Amolong '
'Hinay J et al (2023) Virological characteristics of the SARS-CoV-2 JN.1 '
'variant. Lancet Infect Dis. '
'https://doi.org/10.1016/S1473-3099(23)00813-7',
'DOI': '10.1101/2023.12.08.570782'},
{ 'key': '268_CR51',
'doi-asserted-by': 'publisher',
'unstructured': 'Kaplon H, Chenoweth A, Crescioli S, Reichert JM (2022) Antibodies to '
'watch in 2022. mAbs 14(1):2014296. '
'https://doi.org/10.1080/19420862.2021.2014296',
'DOI': '10.1080/19420862.2021.2014296'},
{ 'key': '268_CR52',
'doi-asserted-by': 'publisher',
'unstructured': 'Ku Z, Xie X, Lin J, Gao P, Sahili AE, Su H et al (2022) Engineering '
'SARS-CoV-2 cocktail antibodies into a bispecific format improves '
'neutralizing potency and breadth. medRxiv. '
'https://doi.org/10.1101/2022.02.01.478504',
'DOI': '10.1101/2022.02.01.478504'},
{ 'key': '268_CR53',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2116620',
'author': 'MJ Levin',
'year': '2022',
'unstructured': 'Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A et al '
'(2022) Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of '
'Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2116620',
'journal-title': 'N Engl J Med'},
{ 'key': '268_CR54',
'doi-asserted-by': 'crossref',
'unstructured': 'Li C, Zhan W, Yang Z, Tu C, Zhu Y, Song W et al (2021) Broad '
'neutralization of SARS-CoV-2 variants by an inhalable bispecific '
'single-domain antibody. Cell. https://doi.org/10.1016/j.cell.2022.03.009',
'DOI': '10.1101/2021.12.30.474535'},
{ 'issue': '3',
'key': '268_CR55',
'doi-asserted-by': 'publisher',
'first-page': 'e336',
'DOI': '10.1093/cid/ciac448',
'volume': '76',
'author': 'Y Lin',
'year': '2023',
'unstructured': 'Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X et al (2023) Nasal spray of '
'neutralizing monoclonal antibody 35B5 confers potential prophylaxis '
'against severe acute respiratory syndrome coronavirus 2 variants of '
'concern: a small-scale clinical trial. Clin Infect Dis 76(3):e336–e341. '
'https://doi.org/10.1093/cid/ciac448',
'journal-title': 'Clin Infect Dis'},
{ 'key': '268_CR56',
'doi-asserted-by': 'crossref',
'unstructured': 'Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D et al (2021) Robust induction '
'of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 '
'vaccine. Cell Discov. https://doi.org/10.1038/s41421-022-00373-7',
'DOI': '10.1101/2021.09.12.21263373'},
{ 'key': '268_CR57',
'doi-asserted-by': 'publisher',
'first-page': '35',
'DOI': '10.1016/j.prrv.2018.12.001',
'volume': '33',
'author': 'MS Luna',
'year': '2020',
'unstructured': 'Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A et al (2020) '
'Expert consensus on palivizumab use for respiratory syncytial virus in '
'developed countries. Paediatr Respir Rev 33:35–44. '
'https://doi.org/10.1016/j.prrv.2018.12.001',
'journal-title': 'Paediatr Respir Rev'},
{ 'issue': '10',
'key': '268_CR58',
'doi-asserted-by': 'publisher',
'first-page': '905',
'DOI': '10.1056/NEJMoa2033130',
'volume': '384',
'author': 'JD Lundgren',
'year': '2021',
'unstructured': 'Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky '
'U et al (2021) A neutralizing monoclonal antibody for hospitalized '
'patients with Covid-19. N Engl J Med 384(10):905–914. '
'https://doi.org/10.1056/NEJMoa2033130',
'journal-title': 'N Engl J Med'},
{ 'key': '268_CR59',
'doi-asserted-by': 'publisher',
'unstructured': 'Martinez DR, Schäfer A, Gobeil S, Li D, De la Cruz G, Parks R et al '
'(2022) A broadly cross-reactive antibody neutralizes and protects '
'against sarbecovirus challenge in mice. Sci Transl Med 14(629):eabj7125. '
'https://doi.org/10.1126/scitranslmed.abj7125',
'DOI': '10.1126/scitranslmed.abj7125'},
{ 'key': '268_CR60',
'doi-asserted-by': 'crossref',
'unstructured': 'McSweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C et al '
'(2022) Stable nebulization and muco-trapping properties of '
'Regdanvimab/IN-006 support its development as a potent, dose-saving '
'inhaled therapy for COVID-19. Bioeng Transl Med. '
'http://doi.org/10.1002/btm2.10391',
'DOI': '10.1101/2022.02.27.482162'},
{ 'issue': '9',
'key': '268_CR61',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.ppat.1009958',
'volume': '17',
'author': 'N Mishra',
'year': '2021',
'unstructured': 'Mishra N, Kumar S, Singh S, Bansal T, Jain N, Saluja S et al (2021) '
'Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly '
'neutralizing antibodies and polyclonal plasma. PLoS Pathog '
'17(9):e1009958. https://doi.org/10.1371/journal.ppat.1009958',
'journal-title': 'PLoS Pathog'},
{ 'issue': '4',
'key': '268_CR62',
'doi-asserted-by': 'publisher',
'first-page': '230',
'DOI': '10.1016/s0968-0004(01)01790-x',
'volume': '26',
'author': 'S Muyldermans',
'year': '2001',
'unstructured': 'Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by '
'single-domain antibody fragments: the superfluous luxury of paired '
'domains. Trends Biochem Sci 26(4):230–235. '
'https://doi.org/10.1016/s0968-0004(01)01790-x',
'journal-title': 'Trends Biochem Sci'},
{ 'key': '268_CR63',
'doi-asserted-by': 'publisher',
'unstructured': 'Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB '
'et al (2021) Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 '
'infections in Syrian hamsters at ultra-low doses. Sci Adv 7(22). '
'https://doi.org/10.1126/sciadv.abh0319',
'DOI': '10.1126/sciadv.abh0319'},
{ 'issue': '2',
'key': '268_CR64',
'doi-asserted-by': 'publisher',
'first-page': '164',
'DOI': '10.1006/clim.2000.4975',
'volume': '98',
'author': 'R Newman',
'year': '2001',
'unstructured': 'Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D et '
'al (2001) Modification of the Fc region of a primatized IgG antibody to '
'human CD4 retains its ability to modulate CD4 receptors but does not '
'deplete CD4+ T cells in chimpanzees. Clin Immunol 98(2):164–174. '
'https://doi.org/10.1006/clim.2000.4975',
'journal-title': 'Clin Immunol'},
{ 'key': '268_CR65',
'doi-asserted-by': 'publisher',
'first-page': '1184',
'DOI': '10.1056/NEJMoa2109682',
'volume': '385',
'author': 'MP O’Brien',
'year': '2021',
'unstructured': 'O’Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N et al '
'(2021) Subcutaneous REGEN-COV antibody combination to prevent Covid-19. '
'N Engl J Med 385:1184–1195. https://doi.org/10.1056/NEJMoa2109682',
'journal-title': 'N Engl J Med'},
{ 'key': '268_CR66',
'doi-asserted-by': 'publisher',
'unstructured': 'Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K et al (2022) '
'Different efficacies of neutralizing antibodies and antiviral drugs on '
'SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Res. '
'https://doi.org/10.1016/j.antiviral.2022.105372',
'DOI': '10.1016/j.antiviral.2022.105372'},
{ 'issue': '6579',
'key': '268_CR67',
'doi-asserted-by': 'publisher',
'first-page': '449',
'DOI': '10.1126/science.abm8143',
'volume': '375',
'author': 'YJ Park',
'year': '2022',
'unstructured': 'Park YJ, De Marco A, Starr TN, Liu Z, Pinto D, Walls AC et al (2022) '
'Antibody-mediated broad sarbecovirus neutralization through ACE2 '
'molecular mimicry. Science 375(6579):449–454. '
'https://doi.org/10.1126/science.abm8143',
'journal-title': 'Science'},
{ 'key': '268_CR68',
'doi-asserted-by': 'publisher',
'unstructured': 'Patel V, Levick B, Boult S, Gibbons DC, Drysdale M, Lloyd EJ et al '
'(2023) Characteristics and outcomes of COVID-19 patients presumed to be '
'treated with sotrovimab in NHS hospitals in England. medRxiv. '
'https://doi.org/10.1101/2023.02.08.23285654',
'DOI': '10.1101/2023.02.08.23285654'},
{ 'issue': '1',
'key': '268_CR69',
'doi-asserted-by': 'publisher',
'first-page': '77',
'DOI': '10.1016/0022-1759(94)00275-2',
'volume': '179',
'author': 'RS Peebles Jr',
'year': '1995',
'unstructured': 'Peebles RS Jr, Liu MC, Lichtenstein LM, Hamilton RG (1995) IgA, IgG and '
'IgM quantification in bronchoalveolar lavage fluids from allergic '
'rhinitics, allergic asthmatics, and normal subjects by monoclonal '
'antibody-based immunoenzymetric assays. J Immunol Methods 179(1):77–86. '
'https://doi.org/10.1016/0022-1759(94)00275-2',
'journal-title': 'J Immunol Methods'},
{ 'key': '268_CR70',
'doi-asserted-by': 'publisher',
'unstructured': 'Piepenbrink MS, Park J-G, Deshpande A, Loos A, Ye C, Basu M et al (2022) '
'Potent universal-coronavirus therapeutic activity mediated by direct '
'respiratory administration of a Spike S2 domain-specific human '
'neutralizing monoclonal antibody. bioRxiv. '
'https://doi.org/10.1101/2022.03.05.483133',
'DOI': '10.1101/2022.03.05.483133'},
{ 'issue': '6559',
'key': '268_CR71',
'doi-asserted-by': 'publisher',
'first-page': '1109',
'DOI': '10.1126/science.abj3321',
'volume': '373',
'author': 'D Pinto',
'year': '2021',
'unstructured': 'Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP et '
'al (2021) Broad betacoronavirus neutralization by a stem helix-specific '
'human antibody. Science 373(6559):1109–1116. '
'https://doi.org/10.1126/science.abj3321',
'journal-title': 'Science'},
{ 'key': '268_CR72',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.annonc.2021.07.015',
'author': 'F Pommeret',
'year': '2021',
'unstructured': 'Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A et al '
'(2021) Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape '
'mutations and secondary clinical deterioration in COVID-19 patients with '
'B-cell malignancies. Ann Oncol. '
'https://doi.org/10.1016/j.annonc.2021.07.015',
'journal-title': 'Ann Oncol'},
{ 'key': '268_CR73',
'doi-asserted-by': 'crossref',
'unstructured': 'Qu P, Xu K, Faraone JN, Goodarzi N, Zheng Y-M, Carlin C et al (2023) '
'Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 Omicron '
'BA.2.86 and FLip variants. Cell. '
'https://doi.org/10.1016/j.cell.2023.12.026',
'DOI': '10.1101/2023.09.11.557206'},
{ 'key': '268_CR74',
'doi-asserted-by': 'publisher',
'unstructured': 'Qu P, Faraone JN, Evans JP, Zheng YM, Carlin C, Anghelina M et al (2023) '
'Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, '
'CH.1.1, and CA.3.1 variants. Cell Rep 42(5):112443. '
'https://doi.org/10.1016/j.celrep.2023.112443',
'DOI': '10.1016/j.celrep.2023.112443'},
{ 'issue': '11',
'key': '268_CR75',
'doi-asserted-by': 'publisher',
'first-page': '815',
'DOI': '10.1016/j.tips.2020.07.004',
'volume': '41',
'author': 'A Renn',
'year': '2020',
'unstructured': 'Renn A, Fu Y, Hu X, Hall MD, Simeonov A (2020) Fruitful neutralizing '
'antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci '
'41(11):815–829. https://doi.org/10.1016/j.tips.2020.07.004',
'journal-title': 'Trends Pharmacol Sci'},
{ 'key': '268_CR76',
'unstructured': 'Reuters (2022) GSK-Vir therapy has neutralising activity against Omicron '
'sub-variant, data shows. Accessed online at '
'https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-vir-therapy-works-against-omicron-sub-variant-data-suggests-2022-02-10/ '
'on 15 Feb 2022'},
{ 'issue': '12',
'key': '268_CR77',
'doi-asserted-by': 'publisher',
'first-page': '6147',
'DOI': '10.1128/aac.01285-13',
'volume': '57',
'author': 'GJ Robbie',
'year': '2013',
'unstructured': 'Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA et '
'al (2013) A novel investigational Fc-modified humanized monoclonal '
'antibody, motavizumab-YTE, has an extended half-life in healthy adults. '
'Antimicrob Agents Chemother 57(12):6147–6153. '
'https://doi.org/10.1128/aac.01285-13',
'journal-title': 'Antimicrob Agents Chemother'},
{ 'key': '268_CR78',
'doi-asserted-by': 'publisher',
'unstructured': 'Sabin AP, Richmond CS, Kenny PA (2022) Emergence and onward transmission '
'of a SARS-CoV-2 E484K variant among household contacts of a '
'bamlanivimab-treated patient. Diagn Microbiol Infect Dis 103(1):115656. '
'https://doi.org/10.1101/2021.10.02.21264415%JmedRxiv',
'DOI': '10.1101/2021.10.02.21264415%JmedRxiv'},
{ 'key': '268_CR79',
'doi-asserted-by': 'publisher',
'unstructured': 'Sanderson T, Hisner R, Donovan-Banfield I, Peacock T, Ruis C (2023) A '
'molnupiravir-associated mutational signature in global SARS-CoV-2 '
'genomes. Nature. https://doi.org/10.1038/s41586-023-06649-6',
'DOI': '10.1038/s41586-023-06649-6'},
{ 'key': '268_CR80',
'doi-asserted-by': 'publisher',
'unstructured': 'Saunders KO (2019) Conceptual approaches to modulating antibody effector '
'functions and circulation half-life. Front Immunol 10. '
'https://doi.org/10.3389/fimmu.2019.01296',
'DOI': '10.3389/fimmu.2019.01296'},
{ 'key': '268_CR81',
'doi-asserted-by': 'publisher',
'unstructured': 'Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S et '
'al (2020) Antibody potency, effector function, and combinations in '
'protection and therapy for SARS-CoV-2 infection in vivoIn vivo efficacy '
'of anti–SARS-CoV-2 antibodies. J Exp Med 218(3). '
'https://doi.org/10.1084/jem.20201993',
'DOI': '10.1084/jem.20201993'},
{ 'issue': '10',
'key': '268_CR82',
'doi-asserted-by': 'publisher',
'first-page': '457',
'DOI': '10.1093/protein/gzw040',
'volume': '29',
'author': 'T Schlothauer',
'year': '2016',
'unstructured': 'Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick '
'C et al (2016) Novel human IgG1 and IgG4 Fc-engineered antibodies with '
'completely abolished immune effector functions. Protein Eng Des Select '
'PEDS 29(10):457–466. https://doi.org/10.1093/protein/gzw040',
'journal-title': 'Protein Eng Des Select PEDS'},
{ 'issue': '5',
'key': '268_CR83',
'doi-asserted-by': 'publisher',
'first-page': '622',
'DOI': '10.1016/S1473-3099(21)00751-9',
'volume': '22',
'author': 'WH Self',
'year': '2022',
'unstructured': 'Self WH, Sandkovsky U, Reilly CS, Vock DM, Gottlieb RL, Mack M et al '
'(2022) Efficacy and safety of two neutralising monoclonal antibody '
'therapies, sotrovimab and BRII-196 plus BRII-198, for adults '
'hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet '
'Infect Dis 22(5):622–635. https://doi.org/10.1016/S1473-3099(21)00751-9',
'journal-title': 'Lancet Infect Dis'},
{ 'key': '268_CR84',
'doi-asserted-by': 'publisher',
'unstructured': 'Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K et al '
'(2023) Sensitivity of BA.2.86 to prevailing neutralising antibody '
'responses. Lancet Infect Dis. https://doi.org/10.1101/2023.09.02.556033',
'DOI': '10.1101/2023.09.02.556033'},
{ 'key': '268_CR85',
'doi-asserted-by': 'publisher',
'unstructured': 'Shrestha LB, Tedla N, Bull RA (2021) Broadly-neutralizing antibodies '
'against emerging SARS-CoV-2 variants. Front Immunol 12:752003. '
'https://doi.org/10.3389/fimmu.2021.752003',
'DOI': '10.3389/fimmu.2021.752003'},
{ 'key': '268_CR86',
'unstructured': 'Some States Still Pushing Ineffective Covid Antibody Treatments (2022). '
'Accessed online at https://www.medscape.com/viewarticle/967020. Accessed '
'on 26 April 2022'},
{ 'key': '268_CR87',
'doi-asserted-by': 'publisher',
'unstructured': 'Song R, Zeng G, Yu J, Meng X, Chen X, Li J et al (2023) Post-exposure '
'prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray '
'for the prevention of symptomatic COVID-19 in healthy adult workers: a '
'randomized, single-blind, placebo-controlled clinical study. Emerg '
'Microbes Infect 2212806. https://doi.org/10.1080/22221751.2023.2212806',
'DOI': '10.1080/22221751.2023.2212806'},
{ 'key': '268_CR88',
'doi-asserted-by': 'crossref',
'unstructured': 'Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ et al '
'(2022a) Determinants of passive antibody efficacy in SARS-CoV-2 '
'infection. Lancet Microbe. https://doi.org/10.1016/S2666-5247(23)00194-5',
'DOI': '10.1101/2022.03.21.22272672'},
{ 'key': '268_CR89',
'doi-asserted-by': 'crossref',
'unstructured': 'Stadler E, Burgess MT, Schlub TE, Chai KL, McQuilten ZK, Wood EM et al '
'(2022b) Monoclonal antibody levels and protection from COVID-19. Nat '
'Commun. https://doi.org/10.1038/s41467-023-40204-1',
'DOI': '10.1101/2022.11.22.22282199'},
{ 'issue': '1',
'key': '268_CR90',
'doi-asserted-by': 'publisher',
'first-page': '6478',
'DOI': '10.1038/s41467-022-33864-y',
'volume': '13',
'author': 'DJ Sullivan',
'year': '2022',
'unstructured': 'Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D (2022) '
'Analysis of anti-Omicron neutralizing antibody titers in different '
'convalescent plasma sources. Nat Comm 13(1):6478. '
'https://doi.org/10.1038/s41467-022-33864-y',
'journal-title': 'Nat Comm'},
{ 'key': '268_CR91',
'doi-asserted-by': 'publisher',
'unstructured': 'Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D '
'(2023) Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 '
'potently neutralizes BQ1.1 and XBB. J General Virol. '
'https://doi.org/10.1101/2022.11.25.517977',
'DOI': '10.1101/2022.11.25.517977'},
{ 'issue': '18',
'key': '268_CR92',
'doi-asserted-by': 'publisher',
'first-page': '2133',
'DOI': '10.1007/s40265-021-01626-7',
'volume': '81',
'author': 'YY Syed',
'year': '2021',
'unstructured': 'Syed YY (2021) Regdanvimab: first approval. Drugs 81(18):2133–2137. '
'https://doi.org/10.1007/s40265-021-01626-7',
'journal-title': 'Drugs'},
{ 'key': '268_CR93',
'doi-asserted-by': 'publisher',
'unstructured': 'Titong A, Gallolu Kankanamalage S, Dong J, Huang B, Spadoni N, Wang B et '
'al (2022) First-in-class trispecific VHH-Fc based antibody with potent '
'prophylactic and therapeutic efficacy against SARS-CoV-2 and variants. '
'Sci Rep 12(1):4163. https://doi.org/10.1038/s41598-022-07952-4',
'DOI': '10.1038/s41598-022-07952-4'},
{ 'issue': '7874',
'key': '268_CR94',
'doi-asserted-by': 'publisher',
'first-page': '103',
'DOI': '10.1038/s41586-021-03817-4',
'volume': '597',
'author': 'MA Tortorici',
'year': '2021',
'unstructured': 'Tortorici MA, Czudnochowski N, Starr TN, Marzi R, Walls AC, Zatta F et '
'al (2021) Broad sarbecovirus neutralization by a human monoclonal '
'antibody. Nature 597(7874):103–108. '
'https://doi.org/10.1038/s41586-021-03817-4',
'journal-title': 'Nature'},
{ 'key': '268_CR95',
'doi-asserted-by': 'crossref',
'unstructured': 'Touret F, Giraud E, Bourret J, Donati F, Tran-Rajau J, Chiaravalli J et '
'al (2022) Enhanced neutralization escape to therapeutic monoclonal '
'antibodies by SARS-CoV-2 Omicron sub-lineages. iScience. '
'https://doi.org/10.1016/j.isci.2023.106413',
'DOI': '10.1101/2022.12.22.521201'},
{ 'key': '268_CR96',
'unstructured': 'Update on AZD7442 STORM CHASER trial in post-exposure prevention of '
'symptomatic COVID-19 (2022). Accessed online at '
'https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html '
'on 21 Feb 2022'},
{ 'key': '268_CR97',
'doi-asserted-by': 'publisher',
'unstructured': 'Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z et al (2023) '
'Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 '
'BA.2.86 variant. Lancet Infect Dis. '
'https://doi.org/10.1016/S1473-3099(23)00575-3',
'DOI': '10.1016/S1473-3099(23)00575-3'},
{ 'key': '268_CR98',
'unstructured': 'US Food and Drug Administration (FDA) (2021) Clinical memorandum Re: EUA '
'26382. Product: COVID-19 Convalescent Plasma. Issued on December 27, '
'2021 at https://www.fda.gov/media/141477/download'},
{ 'key': '268_CR99',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2022.105252',
'volume': '198',
'author': 'L Vangeel',
'year': '2022',
'unstructured': 'Vangeel L, De Jonghe S, Maes P, Slechten B, Raymenants J, André E et al '
'(2022) Remdesivir, Molnupiravir and Nirmatrelvir remain active against '
'SARS-CoV-2 Omicron and other variants of concern. Antiviral Res '
'198:105252. https://doi.org/10.1016/j.antiviral.2022.105252',
'journal-title': 'Antiviral Res'},
{ 'issue': '5',
'key': '268_CR100',
'doi-asserted-by': 'publisher',
'first-page': 'e162',
'DOI': '10.1016/j.jinf.2022.07.014',
'volume': '85',
'author': 'C Vellas',
'year': '2022',
'unstructured': 'Vellas C, Kamar N, Izopet J (2022) Resistance mutations in SARS-CoV-2 '
'Omicron variant after tixagevimab-cilgavimab treatment. J Infect '
'85(5):e162–e163. https://doi.org/10.1016/j.jinf.2022.07.014',
'journal-title': 'J Infect'},
{ 'issue': '2',
'key': '268_CR101',
'doi-asserted-by': 'publisher',
'first-page': '279',
'DOI': '10.1016/j.cell.2022.12.018',
'volume': '186',
'author': 'Q Wang',
'year': '2023',
'unstructured': 'Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y et al (2023b) Alarming '
'antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. '
'Cell 186(2):279–86.e8. https://doi.org/10.1016/j.cell.2022.12.018',
'journal-title': 'Cell'},
{ 'key': '268_CR102',
'doi-asserted-by': 'publisher',
'unstructured': 'Wang X, Jiang S, Jiang S, Li X, Ai J, Lin K et al (2023a) Neutralization '
'of SARS-CoV-2 BQ.1.1 and XBB.1.5 by breakthrough infection sera from '
'previous and current waves in China. bioRxiv. '
'https://doi.org/10.1101/2023.02.07.527406',
'DOI': '10.1101/2023.02.07.527406'},
{ 'key': '268_CR103',
'doi-asserted-by': 'publisher',
'unstructured': 'Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R et al. (2023c) Antibody '
'neutralization of emerging SARS-CoV-2: EG.5.1 and XBC.1.6. bioRxiv. '
'https://doi.org/10.1101/2023.08.21.553968',
'DOI': '10.1101/2023.08.21.553968'},
{ 'key': '268_CR104',
'volume-title': 'Trial in progress: a Phase I/III, randomised, modified double-blind, '
'placebo- and active-controlled pre-exposure prophylaxis study of the '
'SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA)',
'author': 'C Webber',
'year': '2023',
'unstructured': 'Webber C, Beavon R, Thomas S, Chang LA, Cohen T, Perez J (2023) Trial in '
'progress: a Phase I/III, randomised, modified double-blind, placebo- and '
'active-controlled pre-exposure prophylaxis study of the '
'SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA). ECCMID, '
'Copenhagen'},
{ 'issue': '23',
'key': '268_CR105',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2108163',
'volume': '385',
'author': 'DM Weinreich',
'year': '2021',
'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R et al '
'(2021) REGEN-COV antibody combination and outcomes in outpatients with '
'Covid-19. N Engl J Med 385(23):e81. '
'https://doi.org/10.1056/NEJMoa2108163',
'journal-title': 'N Engl J Med'},
{ 'issue': '9',
'key': '268_CR106',
'doi-asserted-by': 'publisher',
'first-page': '3952',
'DOI': '10.1172/jci128437',
'volume': '129',
'author': 'P Weitzenfeld',
'year': '2019',
'unstructured': 'Weitzenfeld P, Bournazos S, Ravetch JV (2019) Antibodies targeting '
'sialyl Lewis A mediate tumor clearance through distinct effector '
'pathways. J Clin Investig 129(9):3952–3962. '
'https://doi.org/10.1172/jci128437',
'journal-title': 'J Clin Investig'},
{ 'issue': '3',
'key': '268_CR107',
'doi-asserted-by': 'publisher',
'first-page': '652',
'DOI': '10.1016/j.jmb.2007.02.024',
'volume': '368',
'author': 'H Wu',
'year': '2007',
'unstructured': 'Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK et al (2007) '
'Development of Motavizumab, an ultra-potent antibody for the prevention '
'of respiratory syncytial virus infection in the upper and lower '
'respiratory tract. J Mol Biol 368(3):652–665. '
'https://doi.org/10.1016/j.jmb.2007.02.024',
'journal-title': 'J Mol Biol'},
{ 'issue': '10369',
'key': '268_CR108',
'doi-asserted-by': 'publisher',
'first-page': '2193',
'DOI': '10.1016/s0140-6736(22)01938-9',
'volume': '400',
'author': 'MY Wu',
'year': '2022',
'unstructured': 'Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H et al (2022a) '
'WHO’s therapeutics and COVID-19 living guideline on mAbs needs to be '
'reassessed. Lancet 400(10369):2193–2196. '
'https://doi.org/10.1016/s0140-6736(22)01938-9',
'journal-title': 'Lancet'},
{ 'key': '268_CR109',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fimmu.2022.865401',
'volume': '13',
'author': 'X Wu',
'year': '2022',
'unstructured': 'Wu X, Wang Y, Cheng L, Ni F, Zhu L, Ma S et al (2022b) Short-term '
'instantaneous prophylaxis and efficient treatment against SARS-CoV-2 in '
'hACE2 mice conferred by an intranasal nanobody (Nb22). Front Immunol '
'13:865401. https://doi.org/10.3389/fimmu.2022.865401',
'journal-title': 'Front Immunol'},
{ 'key': '268_CR110',
'doi-asserted-by': 'publisher',
'unstructured': 'Yamasoba D, Uriu K, Plianchaisuk A, Kosugi Y, Pan L, Zahradnik J et al '
'(2023) Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 '
'variant. Lancet Infect Dis 23(6):655–656. '
'https://doi.org/10.1016/S1473-3099(23)00278-5',
'DOI': '10.1016/S1473-3099(23)00278-5'},
{ 'key': '268_CR111',
'doi-asserted-by': 'publisher',
'unstructured': 'Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X et al (2023a) '
'Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86. '
'Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(23)00573-X',
'DOI': '10.1016/S1473-3099(23)00573-X'},
{ 'key': '268_CR112',
'doi-asserted-by': 'publisher',
'unstructured': 'Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A et al (2023b) Fast '
'evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. '
'Lancet Infect Dis. https://doi.org/10.1101/2023.11.13.566860',
'DOI': '10.1101/2023.11.13.566860'},
{ 'issue': '2',
'key': '268_CR113',
'doi-asserted-by': 'publisher',
'first-page': '157',
'DOI': '10.1038/nbt.1601',
'volume': '28',
'author': 'J Zalevsky',
'year': '2010',
'unstructured': 'Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ et '
'al (2010) Enhanced antibody half-life improves in vivo activity. Nat '
'Biotechnol 28(2):157–159. https://doi.org/10.1038/nbt.1601',
'journal-title': 'Nat Biotechnol'},
{ 'issue': '3',
'key': '268_CR114',
'doi-asserted-by': 'publisher',
'first-page': '415',
'DOI': '10.1093/infdis/jiab247',
'volume': '224',
'author': 'S Zhou',
'year': '2021',
'unstructured': 'Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF et al '
'(2021) β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal '
'mutagenesis but is also mutagenic to mammalian cells. J Infect Dis '
'224(3):415–419. https://doi.org/10.1093/infdis/jiab247',
'journal-title': 'J Infect Dis'},
{ 'key': '268_CR115',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhou H, Tada T, Dcosta BM, Landau NR (2022) SARS-CoV-2 Omicron BA.2 '
'variant evades neutralization by therapeutic monoclonal antibodies. '
'Viruses. https://doi.org/10.3390/v14061334',
'DOI': '10.3390/v14061334'},
{ 'key': '268_CR116',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhou P, Song G, He W-t, Beutler N, Tse LV, Martinez DR et al (2022b) '
'Broadly neutralizing anti-S2 antibodies protect against all three human '
'betacoronaviruses that cause severe disease. Immunity. '
'https://doi.org/10.1016/j.immuni.2023.02.005',
'DOI': '10.1016/j.immuni.2023.02.005'},
{ 'key': '268_CR117',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D et al (2022c) A '
'human antibody reveals a conserved site on beta-coronavirus spike '
'proteins and confers protection against SARS-CoV-2 infection. Sci Transl '
'Med. https://doi.org/10.1126/scitranslmed.abi9215',
'DOI': '10.1126/scitranslmed.abi9215'}],
'container-title': 'Current Topics in Microbiology and Immunology',
'original-title': [],
'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/82_2024_268',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 8, 10]],
'date-time': '2024-08-10T13:04:29Z',
'timestamp': 1723295069000},
'score': 1,
'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/82_2024_268'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024]]},
'references-count': 117,
'URL': 'http://dx.doi.org/10.1007/82_2024_268',
'relation': {},
'ISSN': ['0070-217X', '2196-9965'],
'subject': [],
'published': {'date-parts': [[2024]]},
'assertion': [ { 'value': '11 August 2024',
'order': 1,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ChapterHistory', 'label': 'Chapter History'}}]}
